|
ISIN No
|
INE092O01028
|
BSE Code / NSE Code
|
526075 / VINRKLB
|
Book Value (Rs.)
|
-2.04
|
Face Value
|
5.00
|
|
Bookclosure
|
27/09/2024
|
52Week High
|
47
|
EPS
|
0.00
|
P/E
|
0.00
|
|
Market Cap.
|
22.13 Cr.
|
52Week Low
|
7
|
P/BV / Div Yield (%)
|
-18.03 / 0.00
|
Market Lot
|
1.00
|
|
Security Type
|
Other
|
|
The company history sections lists out major chronological events that happened to the company.
| The Indian pharmaceutical industry is at the center stage in the global pharmaceutical arena and Rekvina is at the forefront in delivering the India centric advantages to the advanced and developing countries of the world. From a small domestic company at inception in middle of 80's, Rekvina has grown formidably to be an integrated, Indian pharmaceutical company with sales in excess of twenty crore INR.
It is with the unwavering 'dedication' and the 'Will to Win ' of Team Rekvina across India that the Company have traversed this journey so far.
The Company is so committed to provide quality medication at affordable prices to the patients with a view to help bring down the healthcare costs & confident that our efforts would see the Company grow from strength to strength in the global space in the years to come. Whilst company continue to enhance the momentum of products, also accelerating drug discovery program through collaborations and alliances.
As Company move ahead & determined to capitalize on the new opportunities based on our strong fundamentals of innovation, entrepreneurship and aggressive marketing. Still the Company remain committed to actively pursue strategy of growth through organic and inorganic means.
Today, Company is well prepared to be amongst the top 100 pharmaceutical companies of India and attain a size of 100 crore INR by 2020. As It stepped into the next phase, driven by our ambition, willing to invest in the growth of our people and business, marching towards the new horizon of global leadership.
Milestone of the Company
This company has introduced the concept of Dispersible Kid Tablets for Pediatric patients. Company's unique formulations include Prestigious product "REKFA", (Essential Fatty Acid - in Capsule, Cream & Pediatric Drop). Enthused by the market response, the group introduced many more specialised quality products for Human Health Care. It has introduced highly specialized products for Gynecological specialty and finally introduced prestigious product REKSEAL (Enbucrilate - n-Butylcyanoacrylate), the Tissue Adhesive which has further added a feather of success to the cap and lead to the introduction of still more specialised products.
Vision Rekvina
To emerge as a global Pharma player. To enter the advanced markets of the world with a sustained presence over the long-term.
Planning proactively to introduce the right products at the right time with the support of WHO-GMP and other quality certifications.
Introducing products in the gynecological disorders and surgical therapeutic segments.
Entering advanced markets with New Chemical Entities (NCE).
Maintaining the highest standards of current Good Manufacturing Practices (cGMP / Revised Schedule-M).
Delivering customer value through a high quality of technical support, analytical data, technical documentation and regulatory compliance.
Generating a cost advantage for its customers and the company through process innovation of raw material efficiency, innovative R&D and engineering.
Making operations safe and reliable by minimizing waste, implementing effective waste treatment and protecting the environment.
Mission Rekvina
While committing to an on-going improvement in performance revolving around effective customer management, Company maintains:
The highest levels of integrity in business conduct,
A strong sense of public responsibility.
To promote and provide an open and participative work environment with growth opportunities for all employees.
2014
-Rekvina Laboratories has splits its face value from Rs 10/- to 5/-
|